Change in Newron Board of Directors
Newron Pharmaceuticals SpA / Key word(s): Personnel
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy - Dec. 1, 2021 - Newron Pharmaceuticals S.p.A. ('Newron', SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Robert Leslie Holland has informed the Board of Directors of his intention to step down as a Non-Executive member of the Board of Directors, effective December 31, 2021.
Ulrich Köstlin, Chairman of Newron, commented: 'The Board of Directors and I would like to thank Bob for his dedication and commitment to Newron since he joined the Board in 2013. During his time at Newron, amongst other milestones achieved, we have seen the approval and launch of our Parkinson's disease product Xadago(R) in key territories including the EU, the USA and Japan, and the advancement of our pipeline product Evenamide into potentially pivotal studies in patients suffering from schizophrenia. He leaves with our sincere thanks and best wishes for the future.'
Robert Leslie Holland is a member of the Company's R&D Committee. At this time, Newron does not anticipate making any Non-Executive Director appointments.
About Newron Pharmaceuticals
For more information
End of ad hoc announcement
|Company:||Newron Pharmaceuticals SpA|
|Via Antonio Meucci 3|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1253502|
|End of Announcement||EQS Group News Service|